Curis, Inc. Presents Preclinical Data for CU-903 at Keystone Symposia Event "PI3 Kinase Signaling in Disease"

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that an oral presentation entitled, "A Single Small Molecule That Inhibits Histone Deacetylase and Phosphatidylinositol-3-Kinase," was presented at the “PI-3 Kinase Signaling in Disease” Keystone Symposia event, which is being held in Olympic Valley, California, April 22-27.

Back to news